Blinatumomab for First-Line Treatment of Children and Young Persons with B-ALL

Data were collected for consecutive children and young persons aged 1-24 years with Philadelphia chromosome–positive or Philadelphia chromosome–negative B-ALL who received blinatumomab as first-line therapy.